Distribution of Intellectual Property. (i) Upon the distribution of the Company’s assets pursuant to this Section 1.2, each Founding Investor or its designated Affiliate will receive, subject to Third Party Rights and Third Party Contracts, (1) a co-exclusive license under Company Intellectual Property Controlled by the Company at the end of the Buy-Out Negotiation Period, for any and all purposes, and (2) a co-exclusive license under Licensed IP licensed to the Company at the end of the Buy-Out Negotiation Period, for any and all purposes within the scope of the license granted to the Company (collectively, the “Distributed IP”); provided, however, that (y) to the extent that one Founding Investor has obtained a license in connection with an Opt-In Election or obtains a license pursuant to Section 1.2(d) or 1.2(e), the licenses to the Distributed IP under this Section 1.2(b) will not include the right to Develop, Manufacture or Commercialize the Program/Project Compounds or Program/Project Therapeutics subject to such Opt-In election or license pursuant to Section 1.2(d) or 1.2(e); and (z) to the extent that a Founding Investor has obtained a license in connection with Section 2.3 of the License Agreement, the licenses to the Distributed IP under this Section 1.2(b) will be subject to such license granted to such Founding Investor. For purposes of this Section 1.2(b)(i), “co-exclusive” means that such license is exercisable by each Founding Investor or its designated Affiliate, and that the Company retains no rights to exercise any such licensed Intellectual Property.
Appears in 3 contracts
Samples: Founding Investor Rights Agreement (Regulus Therapeutics Inc.), Founding Investor Rights Agreement (Alnylam Pharmaceuticals, Inc.), Founding Investor Rights Agreement (Isis Pharmaceuticals Inc)
Distribution of Intellectual Property. (i) Upon the distribution of the Company’s assets pursuant to this Section 1.29.3, each Founding Investor Member or its designated Affiliate will receive, subject to Third Party Rights and Third Party Contracts, (1) a co-exclusive license under Company Intellectual Property Controlled by the Company at the end of the Buy-Out Negotiation Period, for any and all purposes, and (2) a co-exclusive license under Licensed IP licensed to the Company at the end of the Buy-Out Negotiation Period, for any and all purposes within the scope of the license granted to the Company (collectively, the “Distributed IP”); provided, however, that (y) to the extent that one Founding Investor Member has obtained a license in connection with an Opt-In Election or obtains a license pursuant to Section 1.2(d9.3(d) or 1.2(e9.3(e), the licenses to the Distributed IP under this Section 1.2(b9.3(b) will not include the right to Develop, Manufacture or Commercialize the Program/Project Compounds or Program/Project Therapeutics subject to such Opt-In election or license pursuant to Section 1.2(d9.3(d) or 1.2(e9.3(e); and (z) to the extent that a Founding Investor Member has obtained a license in connection with Section 2.3 of the License Agreement, the licenses to the Distributed IP under this Section 1.2(b9.3(b) will be subject to such license granted to such Founding InvestorMember. For purposes of this Section 1.2(b)(i9.3(b)(i), “co-exclusive” means that such license is exercisable by each Founding Investor Member or its designated Affiliate, and that the Company retains no rights to exercise any such licensed Intellectual Property.
Appears in 2 contracts
Samples: Limited Liability Company Agreement (Alnylam Pharmaceuticals, Inc.), Limited Liability Company Agreement (Isis Pharmaceuticals Inc)